Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants. (OT2SUITE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03081832|
Recruitment Status : Completed
First Posted : March 16, 2017
Last Update Posted : January 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Prader-Willi Syndrome||Drug: Oxytocin Other: Control||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)|
|Actual Study Start Date :||January 2017|
|Actual Primary Completion Date :||May 2018|
|Actual Study Completion Date :||December 2018|
Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
- Evaluation of communication skills. [ Time Frame: Day 1 ]Assessed by Vineland-II scale.
- Evaluation of adaptative behavior composite and 3 domains : "Daily living skills", "Socialization", "Motor skills". [ Time Frame: Day 1 ]Assessed by Vineland-II scale.
- Evaluation of behavioral troubles. [ Time Frame: Day 1 ]Assessed by Child Behaviour Check List questionnaire.
- Evaluation of global development. [ Time Frame: Day 2 and 3 ]Assessed by Bayley Scales of Infant and Toddler Development.
- Evaluation of orality and eating behaviour. [ Time Frame: Day 2 ]
- A questionnaire on eating behavior.
- An oral evaluation, which combines a clinical examination carried out by the reference center physician, and the assessment of eating behavior during the meal.
- The fluoroscopy of swallowing.
- Evaluation of brain activity. [ Time Frame: Day 3 ]Assessed by a morphological Magnetic resonance imaging, a resting functional Magnetic resonance imaging.
- Evaluation of plasma levels of ghrelin and other peptides involved in feeding behaviour or energy metabolism. [ Time Frame: Day 1 ]Circulating levels of acylated and non-acylated ghrelin and some peptides and neuropeptides involved in appetite regulation (leptin, cortisol, insulin, Glucagon like peptide-1, pancreatic polypeptide, orexin A, alpha-melanocyte stimulating hormone...).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03081832
|Centre de référence du syndrome de Prader-Willi Hôpital des Enfants|
|Toulouse, France, 31059|
|Principal Investigator:||Maïthé Tauber, Pr||Centre de référence du syndrome de Prader-Willi- CHU Toulouse|